蔚蓝生物(603739) - 2021 Q4 - 年度财报

Financial Performance - The company's operating revenue for 2021 was RMB 1,150,823,565.24, representing a year-on-year increase of 19.85% compared to RMB 960,249,354.36 in 2020[20] - The net profit attributable to shareholders of the listed company for 2021 was RMB 132,573,196.74, an increase of 21.65% from RMB 108,976,210.90 in 2020[20] - The net profit attributable to shareholders after deducting non-recurring gains and losses was RMB 94,250,882.18, reflecting a 9.70% increase from RMB 85,918,294.98 in 2020[20] - The net cash flow from operating activities decreased by 48.26% to RMB 89,513,699.66 from RMB 172,997,190.71 in 2020[20] - The total assets at the end of 2021 were RMB 2,221,761,016.76, a 53.07% increase from RMB 1,451,467,768.17 at the end of 2020[20] - The net assets attributable to shareholders of the listed company increased by 55.16% to RMB 1,604,515,615.36 from RMB 1,034,123,429.61 at the end of 2020[20] - The basic earnings per share for 2021 were RMB 0.54, up 12.50% from RMB 0.48 in 2020[21] - The diluted earnings per share for 2021 were also RMB 0.54, reflecting the same increase of 12.50% from RMB 0.48 in 2020[21] - The weighted average return on equity for 2021 was 9.42%, a decrease of 1.50 percentage points from 10.92% in 2020[21] Research and Development - The company invested RMB 100.94 million in R&D in 2021, accounting for 8.77% of its operating revenue, which is considered high in the industry[28] - The company has a strong R&D team with a balanced academic background, focusing on multi-disciplinary integration to enhance innovation capabilities in the field of probiotics and animal health[41] - The company has applied for 38 invention patents and 12 utility model patents related to probiotics, with 11 patents currently authorized[41] - The company has established 8 technology centers and 2 laboratories, focusing on market-oriented R&D and product innovation[49] - The total R&D investment for the company was RMB 195.02 million, which is competitive within the industry[104] Market Expansion and Strategy - The company plans to expand its human probiotics project, targeting a market that reached nearly RMB 85 billion in 2020[31] - The company is enhancing its service levels and efficiency to support food safety and expand into new markets such as human probiotics[28] - The company is actively exploring and expanding its global layout, particularly in regions such as Russia, Southeast Asia, and Africa, in response to international market dynamics[127] - The company aims to enhance its market network for swine vaccines and provide comprehensive disease prevention solutions for livestock farmers[135] - The company is focusing on the application of microbial technology in the environmental sector, with products already used in various pollution treatment areas, although current revenue from this segment is relatively small[132] Product Development and Innovation - The company has developed 16 proprietary probiotic strains with functions including alleviating gastrointestinal discomfort, improving skin condition, delaying aging, enhancing bone health, boosting immune function, preventing upper respiratory infections, and exhibiting antibacterial and anti-inflammatory properties[41] - The company has launched functional microbial agents for both animal and plant applications, contributing to green farming and addressing environmental concerns[40] - The company has developed and obtained clinical trial approval for several new vaccines, indicating a strong focus on innovation[102] - The company introduced new veterinary products aimed at treating various infections in livestock, including antibiotics and vaccines[93] - The company is the first in China to develop a new veterinary drug for traditional Chinese medicine and a new chemical veterinary drug for pets, indicating a strong innovation capability[97] Environmental and Social Responsibility - The company has been compliant with environmental regulations and has not faced any administrative penalties related to environmental issues during the reporting period[180] - In 2021, the company’s enzyme products helped reduce carbon emissions by approximately 2.0728 million tons[181] - The application of phytase products led to a reduction of about 668,200 tons of dicalcium phosphate usage, resulting in a decrease of 106,900 tons of phosphorus discharge into the environment[181] - The company actively promotes low-carbon initiatives among employees, including energy-saving practices and public transportation usage[184] - The company has successfully conducted 70 training sessions under the "Grow Together with You" initiative, benefiting nearly 3,200 partners and employees by 2021[188] Corporate Governance - The company maintained strict compliance with information disclosure regulations, ensuring timely and accurate reporting of relevant information[141] - The board of directors and supervisory board members actively participated in meetings, fulfilling their responsibilities diligently[141] - The company has not experienced any incidents of information leakage during the preparation of regular reports and significant events[141] - The company’s governance structure is aligned with legal and regulatory requirements, ensuring transparency and accountability[141] - The company has implemented measures to ensure the independence of its assets, personnel, and operations, with no reported issues of related party transactions affecting independence[141] Financial Management and Profit Distribution - The company implements a stable profit distribution policy, ensuring that cash dividends distributed each year are no less than 15% of the distributable profits for that year[166] - The company distributed a cash dividend of 2.00 yuan per 10 shares, totaling 36,012,120 yuan (including tax) based on a total share capital of 180,060,600 shares[169] - The profit distribution policy is subject to review and approval by the board of directors and the shareholders' meeting[169] - The company reported a positive net profit available for distribution to shareholders during the reporting period, but did not propose a cash profit distribution plan[173] - The company emphasizes the importance of independent directors in the decision-making process for profit distribution[172]